This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

Tipranks - Tipranks - Thu Jul 2, 7:02AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME) with bullish sentiments.

4th of July Sale - 70% Off

Nurix Therapeutics (NRIX)

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics, with a price target of $32.00. The company’s shares closed last Tuesday at $24.26.

According to TipRanks.com, Mukherjee is a 5-star analyst with an average return of 28.4% and a 64.5% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Aardvark Therapeutics, Inc., and Perspective Therapeutics. ;'>

Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $33.00, which is a 37.8% upside from current levels. In a report issued on June 29, Oppenheimer also maintained a Buy rating on the stock with a $28.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Taysha Gene Therapies (TSHA)

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Taysha Gene Therapies, with a price target of $14.00. The company’s shares closed last Tuesday at $6.81.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 8.5% and a 53.6% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $12.70, implying an 87.0% upside from current levels. In a report issued on June 23, TipRanks – Google also upgraded the stock to Buy with a $7.00 price target.

Zymeworks (ZYME)

In a report issued on June 29, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks, with a price target of $36.00. The company’s shares closed last Tuesday at $26.14.

PhD has an average return of 17.6% when recommending Zymeworks. ;'>

According to TipRanks.com, PhD is ranked #666 out of 12347 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $38.86 average price target, a 57.6% upside from current levels. In a report issued on June 18, Truist Financial also maintained a Buy rating on the stock.

Read More on NRIX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).